Navigation Links
Metabolex Initiates Phase 2 Trial of Arhalofenate
Date:5/19/2011

HAYWARD, Calif., May 19, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.

This randomized, double-blind, placebo-controlled study will evaluate the safety and urate-lowering activity of 400 and 600 mg of arhalofenate in 60 patients with hyperuricemia and a diagnosis of gout. The primary endpoint of the study is the percent reduction in serum uric acid levels from baseline following four weeks of treatment. As part of its broader Phase 2 program, Metabolex will also be initiating a combination study with allopurinol in patients refractory to allopurinol and a combination study with febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen and Menarini).

Arhalofenate is a novel, orally administered, small molecule uricosuric agent that was previously under development by Metabolex for Type 2 diabetes. Arhalofenate has completed eight Phase 1 and four Phase 2 studies which demonstrate that it has excellent safety and tolerability in more than 550 patients for up to six months of treatment. During this development program, it was observed that once daily dosing with arhalofenate not only lowers glucose and triglycerides, but also results in robust, dose-dependent reductions in serum uric acid through its uricosuric activity. The uric acid reductions were fully retained in patients with mild-to-moderate renal insufficiency. Thus, arhalofenate is a potential best-in-class uricosuric agent that not only corrects the hyperuricemia associated with gout, but also addresses other aspects of metabolic syndrome seen in patients with gout.

"We are excited about initiating our gout trials. Our Phase 2 program is designed to show that a
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Metabolex Announces Election of Kurt von Emster to Board of Directors
2. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
3. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
4. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
5. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
6. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
7. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
8. Stephens Initiates Coverage on Vermillion
9. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
10. American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials
11. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... April 18, 2015 Aurigene ... ) will be presenting data at the poster ... of Cancer Research Annual Meeting (April 18-22 in ...      (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , ... phosphoribosyltransferase (NAMPT) small molecule inhibitors program, which is ...
(Date:4/17/2015)... Horsham, PA (PRWEB) April 17, 2015 ... Tech), a leader in regulatory data management, preparation, and ... announced today the availability of a new Lot Distribution ... that are required to remain compliant with the FDA’s ... Used by the FDA to monitor the volume and ...
(Date:4/17/2015)... April 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... company that develops and commercializes proprietary technologies and ... that it has received approval from the TSX ... outstanding common share purchase warrants ("the Warrants") of ... the Company,s May 2013 private placement financing. ...
(Date:4/17/2015)... -- US-Australian drug discovery company, Novogen, today announced that ... the Feinstein Institute for Medical Research (,Feinstein Institute,) ... collaborate with the objective of developing effective treatments ... together the drug discovery expertise of Novogen and ... Institute in neurosciences and oncology. At ...
Breaking Biology Technology:Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... Wis. - With plans to erect as many as ... Systems is thinking about needs well beyond its existing ... ,Steve Dickmann, Epic's chief administrative officer, said the company anticipates ... existing employee count of 2,500. In addition, there remains plenty ...
... be the answer to a question you aren't even asking ... connect you with your customers - and your customers with ... your reputation and sales. Here are several potential brand threats ... sophisticated, and suggestions for dealing with them. , , Bad ...
... the lower case "i" next to a word as a way ... and glory may be possible, the chances of creating a long-lasting, ... is the exclusive longevity of its unique name, and for that ... Panasonic and not iTV. , ,Terms like interactive and ...
Cached Biology Technology:Epic Systems will build well beyond current staff size 2Protecting your business against online brand abuse 2Protecting your business against online brand abuse 3The I of the storm: iPhones, iPains, and iProblems 2The I of the storm: iPhones, iPains, and iProblems 3The I of the storm: iPhones, iPains, and iProblems 4
(Date:3/18/2015)... , March 18, 2015 As ... businesses, new revolutionary smart wallets and apps continue to be ... currently entrenched in the mobile payment industry in focus today ... Holding Ltd. (NYSE: BABA ), Apple Inc. (NASDAQ: ... ) and Facebook Inc. (NASDAQ: FB ) ...
(Date:3/17/2015)... , March 17, 2015 Emotient, ... analytics software, today announced general availability of ... service for the analysis of facial expressions. The ... advertising, media content, products and services. It delivers ... engagement and sentiment - as derived from facial ...
(Date:3/16/2015)... March 16, 2015 Between ... will present groundbreaking innovations in biometric identification at ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... innovation is well at the forefront: the company,s ... made in Germany . BiometricGate ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... known to be a symptom of physical pain or ... looks to empirical evidence showing that tears have emotional ... analysis by Dr. Oren Hasson of TAU,s Department of ... they also function as an evolution-based mechanism to bring ...
... gracefully swim through the complete darkness of submarine caves, constantly ... of the class Remipedia rely on long antennae ... type of science fiction monster, their head is equipped with ... translations of their Latin names sound menacing. There is the ...
... degeneration of neurons in the midbrain. The mechanisms leading ... unknown. Recent research revealed that about ten per cent ... genes. Furthermore, mitochondria, the cellular powerhouses, seem to play ... LMU Munich under the lead of associate professor Dr. ...
Cached Biology News:Trust in a teardrop 2Scientists discover new species of crustacean on Lanzarote 2When cells run out of fuel 2
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
...
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: